Know Cancer

or
forgot password

A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors


Phase 1/Phase 2
10 Years
N/A
Not Enrolling
Both
Ewing's Sarcoma Family of Tumors

Thank you

Trial Information

A Phase 1/Phase 2 Study Of CP-751,871 In Patients With Relapsed And/Or Refractory Ewing's Sarcoma Family Of Tumors


Inclusion Criteria:



- Ewing's family of tumors

- Current disease state for which there is no curative therapy

Exclusion Criteria:

- Prior anti-IGF-1R therapy

- Concurrent treatment with other anti-cancer agents

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and efficacy, in terms of objective response, of CP-751,871 in this patient population

Outcome Time Frame:

20 months

Safety Issue:

No

Principal Investigator

Pfizer CT.gov Call Center

Investigator Role:

Study Director

Investigator Affiliation:

Pfizer

Authority:

United States: Food and Drug Administration

Study ID:

A4021020

NCT ID:

NCT00560235

Start Date:

March 2008

Completion Date:

October 2012

Related Keywords:

  • Ewing's Sarcoma Family of Tumors
  • Sarcoma, Ewing's
  • Neuroectodermal Tumors, Primitive, Peripheral
  • Sarcoma

Name

Location

Pfizer Investigational Site Rochester, Minnesota  55905
Pfizer Investigational Site Bronx, New York  10461
Pfizer Investigational Site Houston, Texas  77030
Pfizer Investigational Site Federal Way, Washington  98003
Pfizer Investigational Site Clearwater, Florida  33761
Pfizer Investigational Site North Adams, Massachusetts  01247
Pfizer Investigational Site Kingston, Pennsylvania  18704-5535
Pfizer Investigational Site Bristol, Tennessee  37620
Pfizer Investigational Site Providence, Rhode Island  02906